Senators had objected to the financial conflict posed by Robert F. Kennedy Jr.’s decision to retain a financial stake in ...

Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

Contentious hearings to consider Robert F. Kennedy Jr. to lead the Department of Health and Human Services this week have ...

Cigna forecast annual profit below Wall Street expectations on Thursday and missed estimates for the fourth quarter, as ...

Co., Inc. (NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial ...

Tanzania President, Namibia President Elect and Merck Foundation Chief Executive Officer (CEO) named amongst 100 Most ...

Kennedy Jr. earned more than $2.4 million as a consultant referring cases to the law firm Wisner Baum, government records show. Wisner Baum is suing Merck & Co. over allegations that the ...

Merck said the Phase 3 "Hyperion" study, which was evaluating Winrevair versus placebo in recently diagnosed adults with PAH at intermediate or high risk of disease progression, had lost clinical ...

Bank of America Securities analyst Tim Anderson reiterated a Buy rating on Merck & Company (MRK – Research Report) today and set a price ...

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

A significant insider buy by Jennifer Zachary, EVP at Merck & Co MRK , was executed on January 29, and reported in the recent SEC filing. What Happened: A Form 4 filing from the U.S. Securities and ...

Robert F Kennedy Jr and Sen Bernie Sanders had a clash over the senator's links to Big Pharma as Trump's health nominee came ...